
Atul Verma

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2883966/publications.pdf Version: 2024-02-01



Δτιμ //fdma

#	Article	IF	CITATIONS
1	Taking the "pulse―of pulsedâ€field ablation: Realâ€world experience. Journal of Cardiovascular Electrophysiology, 2022, 33, 357-359.	1.7	2
2	First-in-Human Experience and Acute Procedural Outcomes Using a Novel Pulsed Field Ablation System: The PULSED AF Pilot Trial. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010168.	4.8	74
3	Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. Circulation, 2022, 145, 1693-1704.	1.6	54
4	Atrial fibrillation ablation in heart failure: What do we know? What can we do?. Europace, 2021, 23, 353-361.	1.7	5
5	Safety and chronic lesion characterization of pulsed field ablation in a Porcine model. Journal of Cardiovascular Electrophysiology, 2021, 32, 958-969.	1.7	54
6	Safety and feasibility of left bundle branch area pacing following valvular interventions: Multicenter study. Journal of Cardiovascular Electrophysiology, 2021, 32, 2515-2521.	1.7	4
7	Completeness of Linear or Fractionated Electrogram Ablation in Addition to Pulmonary Vein Isolation on Ablation Outcome. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e010146.	4.8	3
8	Primer on Pulsed Electrical Field Ablation. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e010086.	4.8	57
9	The Importance of Arrhythmia Burden for Outcomes and Management Related to Catheter Ablation of Atrial Fibrillation. Korean Circulation Journal, 2021, 51, 477.	1.9	5
10	Post-operative pain following cardiac implantable electronic device implantation: insights from the BRUISE CONTROL trials. Europace, 2021, 23, 748-756.	1.7	7
11	Approach to repeat ablation of atrial fibrillation when the pulmonary veins are already isolated. Journal of Cardiovascular Electrophysiology, 2020, 31, 1869-1871.	1.7	0
12	Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. American Heart Journal, 2020, 219, 128-136.	2.7	12
13	Ablation of persistent atrial fibrillation: Challenges and solutions. Journal of Cardiovascular Electrophysiology, 2020, 31, 1809-1821.	1.7	15
14	In search of durable pulmonary vein isolation. Europace, 2020, 22, 511-512.	1.7	0
15	Relationship between quality of life and burden of recurrent atrial fibrillation following ablation: CAPCOST multicentre cohort study. Europace, 2020, 22, 1017-1025.	1.7	10
16	ls pulmonary vein isolation enough for persistent atrial fibrillation?. Journal of Cardiovascular Electrophysiology, 2020, 31, 2148-2153.	1.7	3
17	Prevalence and clinical impact of spontaneous and adenosine-induced pulmonary vein reconduction in the Contact-Force vs. Cryoballoon Atrial Fibrillation Ablation (CIRCA-DOSE) study. Heart Rhythm, 2020, 17, 897-904.	0.7	7
18	Getting in Contact With AtrialÂFibrillationÂor Not. JACC: Clinical Electrophysiology, 2020, 6, 182-184.	3.2	1

ATUL VERMA

#	Article	IF	CITATIONS
19	Focal source and trigger mapping in atrial fibrillation: Randomized controlled trial evaluating a novel adjunctive ablation strategy. Heart Rhythm, 2020, 17, 683-691.	0.7	22
20	Evaluation of stroke incidence with duty ycled multielectrodeâ€phased radiofrequency ablation of persistent atrial fibrillation results of the VICTORY AF Study. Journal of Cardiovascular Electrophysiology, 2020, 31, 1289-1297.	1.7	1
21	Cryoballoon in persistent atrial fibrillation: a standardized or individualized approach?. Kardiologia Polska, 2020, 78, 1-3.	0.6	0
22	Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (from the REVEAL AF Study). American Journal of Cardiology, 2019, 124, 864-870.	1.6	4
23	Targeting Nonpulmonary Vein Sources in Persistent Atrial Fibrillation Identified by Noncontact Charge Density Mapping. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007233.	4.8	79
24	To continue or stop oral antiâ€coagulation in higherâ€risk patients after a "successful―AF ablation; that is the question. Journal of Cardiovascular Electrophysiology, 2019, 30, 1258-1260.	1.7	2
25	Stopping oral anticoagulation after successful ablation for atrial fibrillation: reality or fiction?. Europace, 2019, 22, 1-2.	1.7	2
26	Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring. Circulation, 2019, 140, 1779-1788.	1.6	345
27	Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007545.	4.8	25
28	Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 2019, 42, e42-e44.	8.6	25
29	Comparison of efficacy of phased multipolar versus traditional radiofrequency ablation: A prospective, multicenter study (CAPCOST). PACE - Pacing and Clinical Electrophysiology, 2019, 42, 942-950.	1.2	5
30	Concomitant anti-platelet therapy in warfarin-treated patients undergoing cardiac rhythm device implantation: A secondary analysis of the BRUISE CONTROL trial. International Journal of Cardiology, 2019, 288, 87-93.	1.7	10
31	Randomized Clinical Trials of Catheter Ablation of Atrial Fibrillation in Congestive Heart Failure. Cardiology Clinics, 2019, 37, 167-176.	2.2	1
32	Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study. Journal of Interventional Cardiac Electrophysiology, 2019, 55, 145-152.	1.3	2
33	The more you look, the more you find. Current Opinion in Cardiology, 2019, 34, 140-146.	1.8	3
34	Uninterrupted anticoagulation with nonâ€vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials. Clinical Cardiology, 2019, 42, 198-205.	1.8	9
35	Real-world comparison of in-hospital Reveal LINQ insertable cardiac monitor insertion inside and outside of the cardiac catheterization or electrophysiology laboratory. American Heart Journal, 2019, 207, 76-82.	2.7	12
36	Intracardiac pulsed field ablation: Proof of feasibility in a chronic porcine model. Heart Rhythm, 2019, 16, 754-764.	0.7	121

ATUL VERMA

#	Article	IF	CITATIONS
37	High-resolution noncontact charge-density mapping of endocardial activation. JCI Insight, 2019, 4, .	5.0	61
38	Long-Term Outcomes of Post-OperativeÂAtrial Fibrillation. Journal of the American College of Cardiology, 2018, 71, 749-751.	2.8	8
39	The Optimal Anti-Coagulation for Enhanced-Risk Patients Post–Catheter Ablation for Atrial Fibrillation (OCEAN) trial. American Heart Journal, 2018, 197, 124-132.	2.7	50
40	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. Europace, 2018, 20, 395-407.	1.7	95
41	Novel multipolar mapping system identifying coexistence of multiple conduction patterns in persistent AF: A case report. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 210-213.	1.2	6
42	Contact force sensing for ablation of persistent atrial fibrillation: A randomized, multicenter trial. Heart Rhythm, 2018, 15, 201-208.	0.7	52
43	Does "Secondary―Atrial Fibrillation Really Exist?. JACC: Clinical Electrophysiology, 2018, 4, 394-396.	3.2	3
44	Postablation Atrial Fibrillation Burden and Patient Activity Level: Insights From the DISCERN AF Study. Journal of the American Heart Association, 2018, 7, e010256.	3.7	15
45	Prevention of venous thrombosis after electrophysiology procedures: a survey of national practice. Journal of Interventional Cardiac Electrophysiology, 2018, 53, 357-363.	1.3	5
46	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2018, 34, 1371-1392.	1.7	195
47	A randomized clinical trial of early invasive intervention for atrial fibrillation (EARLY-AF) - methods and rationale. American Heart Journal, 2018, 206, 94-104.	2.7	22
48	Characterization and significance of localized sources identified by a novel automated algorithm during mapping of human persistent atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2018, 29, 1480-1488.	1.7	41
49	Longâ€term risk of stroke and bleeding post–atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 2018, 29, 1355-1362.	1.7	15
50	Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). European Heart Journal, 2018, 39, 3973-3979.	2.2	131
51	Measuring Success in Ablation of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006582.	4.8	6
52	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?. Journal of Arrhythmia, 2018, 34, 99-123.	1.2	41
53	Persistent Atrial Fibrillation Ablation: Where Do We Go From Here?. Canadian Journal of Cardiology, 2018, 34, 1471-1481.	1.7	16
54	Catheter Ablation of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006484.	4.8	0

ATUL VERMA

#	Article	IF	CITATIONS
55	Effect of Different Cutpoints for Defining Success Post-Catheter Ablation for Persistent Atrial Fibrillation. JACC: Clinical Electrophysiology, 2017, 3, 522-523.	3.2	5
56	Should Ablation Be First-Line Therapy for Patients with Paroxysmal AF?. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 38.	0.9	0
57	Impact of acute atrial fibrillation termination and prolongation of atrial fibrillation cycle length on the outcome of ablation of persistent atrial fibrillation: A substudy of the STAR AF II trial. Heart Rhythm, 2017, 14, 476-483.	0.7	51
58	Risk of Stroke and Recurrence After AF Ablation in Patients With an Initial Eventâ€Free Period of 12 Months. Journal of Cardiovascular Electrophysiology, 2017, 28, 273-279.	1.7	14
59	The Impact of Duration of Atrial Fibrillation Recurrences on Measures of Healthâ€Related Quality of Life and Symptoms. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 166-172.	1.2	20
60	Ablation of complex fractionated electrograms may not be useful for catheter ablation of persistent atrial fibrillation. Heart Rhythm, 2016, 13, 2101-2103.	0.7	4
61	Multipolar ablation for atrial fibrillation: are we going in circles?. Europace, 2016, 18, 631-632.	1.7	0
62	Predictors for Progression of Atrial Fibrillation in Patients Awaiting Atrial Fibrillation Ablation. Canadian Journal of Cardiology, 2016, 32, 1348-1354.	1.7	29
63	The 2014 Atrial Fibrillation Guidelines Companion: AÂPractical Approach to the Use of the Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology, 2015, 31, 1207-1218.	1.7	43
64	Catheter ablation for asymptomatic atrial fibrillation?. Expert Review of Cardiovascular Therapy, 2015, 13, 243-248.	1.5	1
65	Substrate-guided ablation of haemodynamically tolerated and untolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome. Europace, 2015, 17, 461-467.	1.7	62
66	2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2014, 30, 1114-1130.	1.7	382
67	Comparison of Outcomes After Cardioversion or Atrial Fibrillation Ablation in Patients With Differing Periprocedural Anticoagulation Regimens. Canadian Journal of Cardiology, 2014, 30, 1541-1546.	1.7	27
68	Canadian Heart Rhythm Society and Canadian Association of Radiologists Consensus Statement on Magnetic Resonance Imaging With Cardiac Implantable ElectronicÂDevices. Canadian Journal of Cardiology, 2014, 30, 1131-1141.	1.7	32